Oxford researchers have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need for booster shots and increasing immunisation coverage in hard-to-reach communities.
Kennedy DPhil student Chrissy Bolton has been awarded Best Abstract in Basic and Translational Science at the European Alliance of Associations for Rheumatology 2025 (EULAR) conference.
Professor Marco Fritzsche from the Kennedy Institute of Rheumatology, is co-leading a research project that has been awarded a \u00a31.4 million Programme Foundation Award from Cancer Research UK, to investigate how physical forces within tumours affect the ability of a type of white blood cell to attack and eliminate cancer cells.
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs) - a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and revolutionise cancer treatment for patients.
Researchers at the Botnar Institute have joined a new consortium that has been awarded \u00a33m from the charity Versus Arthritis to bring world-leading experts from five UK universities together to accelerate clinical epidemiology research, which will help answer pressing questions from those living with arthritis.
Professor Andrew Carr was honoured in the 2025 King\u2019s Birthday Honours List being awarded an MBE for services to Orthopaedic Research and Training.
A new study to better understand the deadly bone cancer chondrosarcoma aims to reveal potential 'weak spots' of the disease with the ultimate goal of developing more effective treatments for patients.
Laura Coates presents the results from the 'SPEED' trial that found early use of biologic therapy or combination conventional DMARDs may be more effective than standard step-up care with methotrexate for psoriatic arthritis patients with poor prognostic factors.
NDORMS researchers have identified a primary source of inflammatory IL-17 driving spondyloarthritis, paving the way for the development of targeted therapies to treat the condition.
The Bone Cancer Research Trust and Sarcoma UK are joining forces to launch two groundbreaking research projects which could support the early diagnosis of primary bone cancer.
Professor of Orthopaedic Surgery Amar Rangan has been recognised as an exceptional health scientist in his election as a Fellow of the Academy of Medical Sciences.
A team at NDORMS, University of Oxford has successfully administered a pioneering treatment to a patient with XIAP deficiency, a rare genetic disorder.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues\u2014addressing a major challenge in current immunotherapy.
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Dr Karthik Ramasamy and team will assess a new mass spectrometry-based monitoring technique for its ability to predict and identify early disease relapse.
Researchers at the University of Oxford have developed a new drug delivery system using ultrasound-activated nanoparticles to break through and destroy bacterial biofilms. This offers a promising solution that could address the global crisis of chronic antibiotic-resistant infections affecting hundreds of millions of people worldwide.
![\"Mosquito](\"https://www.ndorms.ox.ac.uk/news/2018single-shot2019-malaria-vaccine-delivery-system-could-transform-global-immunisation/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n